Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A tribute to Jan Gosta Waldenström.
Kyle RA, Anderson KC. Kyle RA, et al. Among authors: anderson kc. Blood. 1997 Jun 15;89(12):4245-7. Blood. 1997. PMID: 9192746 Free article. No abstract available.
Benzene and multiple myeloma: appraisal of the scientific evidence.
Bergsagel DE, Wong O, Bergsagel PL, Alexanian R, Anderson K, Kyle RA, Raabe GK. Bergsagel DE, et al. Among authors: anderson k. Blood. 1999 Aug 15;94(4):1174-82. Blood. 1999. PMID: 10438704 Free article. Review. No abstract available.
Thalidomide: emerging role in cancer medicine.
Richardson P, Hideshima T, Anderson K. Richardson P, et al. Among authors: anderson k. Annu Rev Med. 2002;53:629-57. doi: 10.1146/annurev.med.53.082901.104043. Annu Rev Med. 2002. PMID: 11818493 Review.
Thalidomide in multiple myeloma.
Richardson P, Hideshima T, Anderson K. Richardson P, et al. Among authors: anderson k. Biomed Pharmacother. 2002 May;56(3):115-28. doi: 10.1016/s0753-3322(02)00168-3. Biomed Pharmacother. 2002. PMID: 12046682 Review.
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, Zeldis J, Dalton W, Anderson K. Richardson P, et al. Among authors: anderson k. Mayo Clin Proc. 2004 Jul;79(7):875-82. doi: 10.4065/79.7.875. Mayo Clin Proc. 2004. PMID: 15244383 Clinical Trial.
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Berenson JR, et al. Among authors: anderson k. Cancer. 2005 Nov 15;104(10):2141-8. doi: 10.1002/cncr.21427. Cancer. 2005. PMID: 16206291 Free article. Clinical Trial.
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Richardson PG, Schlossman R, Mitsiades C, Hideshima T, Munshi N, Anderson K. Richardson PG, et al. Among authors: anderson k. Clin Lymphoma Myeloma. 2005 Sep;6(2):84-8. doi: 10.3816/CLM.2005.n.033. Clin Lymphoma Myeloma. 2005. PMID: 16231845 Review.
8,315 results